NeoImmuneTech네오이뮨텍
950220 · KOSDAQ · ₩950220 · 네오이뮨텍
₩1,632▼ ₩45 (2.68%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | −533.9% | −26,596.6% | −23,497.6% | — | — | — |
| Operating margin | −1,219.4% | −26,596.6% | −23,497.6% | — | — | — |
| Net margin | −1,430.9% | −33,531.5% | −23,994.5% | — | — | — |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +1,681.6% | −46.6% | — | — | — | — |
| Operating income growth | +18.3% | +39.6% | +31.1% | +5.4% | +0.7% | — |
| Net income growth | +24.0% | +25.4% | +26.7% | +12.5% | −2.0% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −43.7% | −64.2% | −69.4% | −53.7% | −40.5% | −33.6% |
| Return on assets | −31.9% | −44.0% | −52.3% | −45.3% | −34.9% | −29.1% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 35.1% | 38.6% | 57.0% | 20.9% | 16.9% | 15.4% |
| Net debt to equity | −49.4% | −72.1% | −65.4% | −81.5% | −86.5% | −84.9% |
| Current ratio | 283.0% | 308.4% | 189.2% | 560.7% | 719.5% | 816.8% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: NeoImmuneTech / 네오이뮨텍 / 950220 / KRX:950220
Source: KRX statistical information